INF39

立即咨询

INF39

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

866028-26-4

包装与价格：

包装	价格(元)
2mg	询价
5mg	询价
25mg	询价

化学性质

Storage	Store at -20°C
M.Wt	224.68
Cas No.	866028-26-4
Formula	C₁₂H₁₃ClO₂
Solubility	≥22.5 mg/mL in DMSO; ≥41.9 mg/mL in H2O; ≥47.9 mg/mL in EtOH
Chemical Name	ethyl 2-(2-chlorobenzyl)acrylate
Canonical SMILES	CCOC(C(CC1=CC=CC=C1Cl)=C)=O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

INF39 is a nontoxic, irreversible inhibitor of the nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing protein 3 (NLRP3). NLRP3 is an intracellular sensor that detects a variety of endogenous danger signals, microbial motifs as well as environmental irritants, resulting in the formation and activation of the NLRP3 inflammasome. Assembly of the NLRP3 inflammasome leads to caspase 1-dependent release of pro-inflammatory cytokines (e.g. IL-1β and IL-18), as well as to gasdermin D-induced pyroptotic cell death. Pharmacological inhibition of NLRP3 inflammasome activation has been shown to offer a new option in the treatment of inflammatory bowel disease.

References:

1. Cocco M, Pellegrini C, Martínez-Banaclocha H, et al. Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry, 2017, 60(9): 3656-3671.

2. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nature Reviews Immunology, 2019, 19(8): 477-489.

试验操作

Cell experiment:[1]
Cell lines	LPS-primed mouse bone marrow derived macrophages (BMDMs)
Reaction Conditions	10 or 100 μM INF39 for 1 h incubation
Applications	INF39 was able to significantly inhibit ATP- and nigericin-induced IL-1β release at 10 μM. Furthermore, INF39 reduced caspase-1 activation and pyroptosis in these macrophages.
Animal experiment:[1]
Animal models	Male Sprague-Dawley rats, 200 ~ 250 g
Dosage form	12.5, 25.0, 50.0 mg/kg Once daily by intragastric route for 6 days
Applications	Oral administration of INF39 reduced systemic and colonic Inflammation in rats treated with 2,4-dinitrobenzenesulfonic acid (DNBS). Meanwhile, INF39 dose-dependently attenuated increment of spleen weight and decrease in colonic length caused by DNBS.
Note	The technical data provided above is for reference only.
	References: 1. Cocco M, Pellegrini C, Martínez-Banaclocha H, et al. Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry, 2017, 60(9): 3656-3671. 2. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nature Reviews Immunology, 2019, 19(8): 477-489.